H(II) Mesophase and Peptide Cell-penetrating Enhancers for Improved Transdermal Delivery of Sodium Diclofenac
Overview
Affiliations
This study develops a novel transdermal delivery vehicle for the enhanced delivery of sodium diclofenac (Na-DFC). The system utilizes the advantages of reversed hexagonal lyotropic liquid crystals (H(II)LC), combined with a peptide cell penetration enhancer (CPE), creating together an adaptable system that provides versatile options in the field of transdermal delivery. This enhancer peptide is based on a family of amphipatic peptides that exhibit improved membrane permeability. Franz permeation cell experiments revealed that the peptide enhancer (RALA) improved Na-DFC skin penetration of the liquid crystal 2.2-fold. We studied the structural effects of RALA solubilization on the H(II) mesophase. RALA acts as a chaotropic agent, interfering in the structure of the water, and causes a measurable swelling of the aqueous cylinders by 5A. Small angle X-ray scattering (SAXS) and attenuated total reflectance-Fourier transform infrared (ATR-FTIR) measurements reveal enhanced hydration of the glycerol monooleate (GMO) headgroups and a 6.5% increase in the fraction of non-freezable water resulting from RALA incorporation. RALA caused a gradual increase in the GMO effective headgroup area due to the hydration, leading eventually to a transform of the hexagonal structure towards a lamellar one. Circular dichroism and ATR-FTIR measurements showed a conservation of the peptide structure when incorporated into the H(II) mesophase. The combined H(II)LC-CPE systems can serve as high potential vehicles for a variety of drugs, as they can easily be modified by varying the composition and temperature, according to the required dose and delivery features.
Panda P, Mohanty T, Mohapatra R AAPS PharmSciTech. 2025; 26(1):29.
PMID: 39789371 DOI: 10.1208/s12249-024-03029-9.
Huang Y, Gui S RSC Adv. 2022; 8(13):6978-6987.
PMID: 35540315 PMC: 9078419. DOI: 10.1039/c7ra12008g.
Monoolein Assisted Oil-Based Transdermal Delivery of Powder Vaccine.
Kitaoka M, Oka A, Goto M Pharmaceutics. 2020; 12(9).
PMID: 32867263 PMC: 7558954. DOI: 10.3390/pharmaceutics12090814.
Xingqi W, Yong Z, Xing L, Yang W, Jie H, Rongfeng H Drug Deliv. 2019; 26(1):952-964.
PMID: 31544551 PMC: 6764361. DOI: 10.1080/10717544.2019.1667451.
Gao S, Tian B, Han J, Zhang J, Shi Y, Lv Q Int J Nanomedicine. 2019; 14:6135-6150.
PMID: 31447556 PMC: 6683961. DOI: 10.2147/IJN.S205295.